Trials / Completed
CompletedNCT01309763
Safety and Tolerability of AFFITOPE AD03
A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess the Tolerability and Safety of Repeated Administrations of a Single-dose of AFFITOPE AD03 to Alzheimer's Disease Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Affiris AG · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, controlled, parallel group, patient-blinded, single-center, phase I pilot study to assess tolerability and safety of repeated subcutaneous administration of a single-dose of AFFITOPE AD03 applied with or without adjuvant to patients with mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFFITOPE AD03 | s.c. injection |
| BIOLOGICAL | AFFITOPE AD03 + Alum | s.c. injection |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-09-01
- Completion
- 2011-11-01
- First posted
- 2011-03-07
- Last updated
- 2011-12-20
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT01309763. Inclusion in this directory is not an endorsement.